Evidence map›Paper›PMID 35212780›Full record

ArticleCancer chemotherapy and pharmacology2022

Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.

Zejia Yang, Jipei Liao, Rena G Lapidus, Xiaoxuan Fan, Ranee Mehra, Kevin J Cullen, Hancai Dan

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zejia YangUniversity of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Jipei LiaoUniversity of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Rena G LapidusUniversity of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Xiaoxuan FanUniversity of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Ranee MehraUniversity of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Kevin J CullenUniversity of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. kcullen@umm.edu.
Hancai DanUniversity of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. HDan@som.umaryland.edu.ORCID 0000-0003-0332-8290
University of Maryland, Baltimore · US

Funding

Inhibition of castration resistant prostate cancer by targeting of the IKKbeta/AR signalingR01CA212094 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI DAN, HANCAI · 2017 to 2021
$1.8M
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC ProgressionR00CA149178 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI DAN, HANCAI · 2013 to 2015
$709k
NIH HHS R00CA149178NIH HHS R01CA212094
6 · The paper itself

Abstract

purposeWe investigated the role of Wee1 kinase in cisplatin-resistant head and neck squamous cell carcinoma (HNSCC) in multiple cisplatin-resistant HNSCC cell lines and determined the efficacy of either Wee1 inhibitor, AZD1775 alone, or in combination with cisplatin, on cisplatin-resistant HNSCC inhibition.

methodsPhosphorylation and total protein levels of cells were assessed by Western blot analysis. Cell viability and apoptosis were examined by MTS assay and flow cytometry, respectively.

resultsWee1 kinase protein expression levels in five cisplatin-resistant HNSCC cell types were higher than those in their parental cisplatin-sensitive partners. Importantly, Wee1 knockdown inhibited cell proliferation and re-sensitized cells to cisplatin treatment. Interestingly, previous studies have also shown that Wee1 inhibitor AZD1775 synergizes with cisplatin to suppress cell proliferation of cisplatin-sensitive HNSCC. We found that AZD1775 inhibited both cisplatin-sensitive and resistant HNSCC with similar IC

conclusionWee1 inhibitor, AZD1775, and cisplatin coordinately suppressed proliferation and survival of HNSCC.

Indexed as

CisplatinHead and Neck NeoplasmsApoptosisCell Cycle ProteinsCell Line, TumorCell ProliferationHumansProtein-Tyrosine KinasesSquamous Cell Carcinoma of Head and NeckCell Cycle ProteinsCisplatinProtein-Tyrosine KinasesWEE1 protein, humanAZD1775Cisplatin resistanceHead and neck squamous cell carcinomaHNSCCWee1Wee1 inhibitor

Identifiers

PMID35212780
OpenAlexW4214486964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.